Abstract:Based on our hypothesis that epitope vaccine may be a new strategy to induce high levels of neutralization antibodies against HIV–1, we prepared multiple–epitope vaccines using three neutralizing epitopes (GPGRAFY, RILAVERYLKD and ELDKWA) of HIV–1 gp160, and characterized their immunogenicity. Peptide 1 [C–G–(ELDKWA–GPGRAFY)2–K] and peptide 2 (CG–GPGRAFY–ELDKWA–G–RILAVERYLKD) were synthesized and conjugated with carrier protein bovine serum albumin (BSA). After vaccination antibody responses to these immunogens were induced and evaluated by ELISA. The C–G–(ELDKWA–GPGRAFY)2–K–BSA (BSA: carrier protein) multiple–epitope vaccine induced a strong antibody response to the C–G–(ELDKWA–GPGRAFY)2–K peptide (antibody titer: 1:25,600) and C–(ELDKWAG)4 peptide (antibody titer: 1:12,800), but a weak antibody response to the C–(GPCGRAFY)4 peptide. The CG–GPGRAFY–ELDKWA–G–RILAVERYLKD–K–BSA (BSA: carrier protein) multiple–epitope vaccine also induced strong antibody response to the CG–GPGRAFY–ELDKWA–G–RILAVERYLKD–K peptide (antibody titer: 1:25,600) and C–(ELLDKWAG)4 peptide (antibody titer: 1:6,400), a very strong response to C–(RIVALVERYLKD–G)2–K peptide (dilution: 1:102,400), and a very weak response to the C–(GPGRAFY)4 peptide (dilution: 1:400) in mice. Both antisera induced by both multiple–epitope vaccines interacted with the recombinant soluble gp41 (rgp41), but did not bind two control peptides. In comparison with both epitope vaccines, the rgp160 subunit vaccine could induce weak epitope–specific antibody response to these three epitopes on the three epitope peptides and V3, N–domain and C–domain peptides (dilution: 1:400–1:1,600). These results indicate that both multiple–epitope vaccines could induce high levels of antibodies to both neutralizing epitopes RILAVERYLKD and ELDKWA, while the GPGRAFY epitope on both vaccines appeared to have weak immunogenicity. Both multiple–epitope vaccines showed significant potency on inducing high levels of epitope–specific neutralization antibodies in comparison with rgp160 subunit vaccine.

The Immunologic Dominance of an Epitope Within a Rationally Designed Poly-Epitope Vaccine is Influenced by Multiple Factors.

In Silicodesign of a DNA-based HIV-1 Multi-Epitope Vaccine for Chinese Populations

Immunoinformatic Identification of Multiple Epitopes of gp120 Protein of HIV-1 to Enhance the Immune Response against HIV-1 Infection

V3ctl Epitope Density in A Single Recombinant Molecule Antigen Differentially Affects the Number and Activity of Primary and Memory Cd8(+) T Cells

An Immunogen Containing Four Tandem 10E8 Epitope Repeats with Exposed Key Residues Induces Antibodies That Neutralize HIV-1 and Activates an ADCC Reporter Gene.

Epitope-vaccine strategy against HIV-1: today and tomorrow.

Neutralizing Epitopes in the Membrane-Proximal Region of Hiv-1 Gp41: Genetic Variability and Co-Variation

Sequential priming and boosting with heterologous HIV immunogens predominantly stimulated T cell immunity against conserved epitopes.

Immunogenicity of Neutralizing Epitopes on Multiple–Epitope Vaccines Against HIV–1

Epitope-Vaccines: A New Strategy to Induce High Levels of Neutralizing Antibodies Against Hiv-1

Effective assessment of CD4 T cell Immunodominance patterns: impact of antigen processing and HLA restriction

Design and construction of a recombinant epitope-peptide gene as a universal epitope-vaccine strategy.

Immunodominance Analysis Through Interactions of CD8+ T Cells and DCs in Lymph Nodes

Epitope-focused Immunogens Against the CD4-binding Site of HIV-1 Envelope Protein Induce Neutralizing Antibodies Against Auto- and Heterologous Viruses

In silico designing of novel epitope-based peptide vaccines against HIV-1

The Neutralizing Epitope ELDKWA on HIV-1 Gp41: Genetic Variability and Antigenicity

Reverse vaccinology approaches to design a potent multiepitope vaccine against the HIV whole genome: immunoinformatic, bioinformatics, and molecular dynamics approaches

Multi-Epitope Vaccine Design Using an Immunoinformatic Approach for SARS-CoV-2

Highly conserved, non-human-like, and cross-reactive SARS-CoV-2 T cell epitopes for COVID-19 vaccine design and validation

Repeated Epitope In The Recombinant Epitope-Peptide Could Enhance Eldkwa-Epitope-Specific Antibody Response

T cell epitope mapping reveals immunodominance of evolutionarily conserved regions within SARS-CoV-2 proteome.